Tolvaptan News and Research

RSS

Tolvaptan is a vasopressin V2 receptor blocker that shows promise for management of heart failure.

FDA approves Samsca (tolvaptan) to treat hyponatremia

The U.S. Food and Drug Administration has approved Samsca tablets (tolvaptan) to treat hyponatremia, an abnormally low concentration of sodium in the blood.

22 May 2009

FDA approves Samsca tablets (tolvaptan) to treat hyponatremia

The U.S. Food and Drug Administration has approved Samsca tablets (tolvaptan) to treat hyponatremia, an abnormally low concentration of sodium in the blood.

8 May 2009

FDA advisory committee recommends approval of Tolvaptan for hyponatremia

The U.S. Food and Drug Administration (FDA) Advisory Committee on Cardiovascular and Renal Drugs voted to recommend the approval of tolvaptan, Otsuka Pharmaceutical Development & Commercialization, Inc.'s (OPDC) investigational treatment for patients with hyponatremia.

25 Jun 2008

Investigational drug tolvaptan treats hyponatremia

Results of the two largest studies on hyponatremia, SALT-1 and SALT-2, presented Nov. 14 at the American Heart Association's Scientific Sessions in Chicago, found that the investigational drug tolvaptan treated hyponatremia -- water intoxication -- faster and more effectively than available treatments.

14 Nov 2006

Serum sodium level is a major predictor of a poor prognosis for heart failure patients

Research presented today at the American College of Cardiology's Scientific Sessions in Orlando pinpoints a major marker of a poor prognosis for heart failure, hyponatremia, or a lower than normal concentration of serum or blood sodium.

7 Mar 2005